BioWorld

May 26, 2009

JNJ Captures Cougar in $970M Purchase

Johnson & Johnson went a long way toward strengthening its oncology pipeline, agreeing to buy Cougar Biotechnology Inc. in a deal worth just under $1 billion. (BioWorld Today) Read More

Patient Death Halts Aastrom's Cardiac Cell Therapy Study

HHS Directing $1B for H1N1 Swine Flu Vaccine

BIO Meeting 'Not Downbeat' Despite Economy, Politicking

Holiday Notice

Financings Roundup

Appointments And Advancements

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 23, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

Nankai University and Accendatech present new majusculamide D derivatives

BioWorld Science

Scientists from Nankai University Tianjin and Accendatech Technology Co. Ltd. have identified a majusculamide D derivative found to be useful for the treatment of...